Takeda, Shire Finally Seal £46bn Deal
Persistence pays off for Takeda as it reaches a confirmed deal for the acquisition of Shire after a dogged pursuit, paving the way for the largest ever M&A transaction both in the Japanese pharma sector and by any Japanese company of an overseas target.
You may also be interested in...
A look back at the Scrip stories that piqued the most interest for our readers in 2018.
Stakeholders are eager for details on the Takeda/Shire merger and on what Trump said to Pfizer CEO Ian Read to cause the recent about-face on price increases. Other key topics will be status updates on Teva's Copaxone franchise and on Novo Nordisk's oral semaglutide.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.